NEW YORK, June 22, 2017 /PRNewswire/ --
If you want a Stock Review on CYTR, KERX, TGTX or ZIOP then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Biotechnology is an industry that focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Companies in this
Los Angeles, California headquartered CytRx Corp.'s shares gained 4.28%, closing Wednesday's trading session at $0.67. The stock recorded a trading volume of 4.48 million shares. The Company's shares have surged 21.72% in the last month, 68.19% over the previous three months, and 78.72% since the start of this year. The stock is trading 17.44% above its 50-day moving average and 34.33% above its 200-day moving average. Additionally, shares of CytRx, which operates as a biopharmaceutical research and development company specializing in oncology, have a Relative Strength Index (RSI) of 52.18.
On June 13th, 2017, CytRx announced that Shanta Chawla, M.D., who has served as the Company's Vice President of Clinical Development since 2014, is being promoted to Senior Vice President of Drug Development, and will assume the leadership of the Company's on-going clinical drug development and regulatory functions. Chawla, who is a Board certified physician, has played a key role in the late-stage development and NDA submissions of several oncology drugs, and has been involved in the day-to-day clinical development of aldoxorubicin for more than three years. See our free and comprehensive research report on CYTR at:
On Wednesday, shares in Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc. recorded a trading volume of 1.45 million shares, which was above their three months average volume of 1.35 million shares. The stock edged 3.94% higher, ending the day at $6.33. The Company's shares have advanced 0.16% in the past month, 16.15% in the previous three months, and 8.02% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.80% and 13.14%, respectively. Furthermore, shares of Keryx Biopharma, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 51.69. KERX free research report is just a click away at:
New York headquartered TG Therapeutics Inc.'s stock finished the day 3.15% higher at $11.45. A total volume of 1.74 million shares was traded, which was above their three months average volume of 1.70 million shares. Shares of the Company have advanced 3.15% in the previous three months and 146.24% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.94% and 45.35%, respectively. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 49.93.
On June 16th, 2017, TG Therapeutics recapped clinical data from its Phase-3 GENUINE trial of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody in combination with ibrutinib, the BTK inhibitor. The GENUINE Phase-3 trial showed that adding TG-1101 to ibrutinib could improve overall response rate, CR rate, and MRD negativity in patients with high-risk Chronic Lymphocytic Leukemia. Sign up for your complimentary report on TGTX at:
Shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. ended yesterday's session 1.90% higher at $5.89. The stock recorded a trading volume of 1.10 million shares. The Company's shares have advanced 1.38% over the previous three months and 10.09% since the start of this year. The stock is trading 4.60% below its 200-day moving average. Moreover, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 46.38.
On June 01st, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $9.50 per share.
On June 05th, 2017, ZIOPHARM Oncology announced updated results from its Phase-1 multicenter study of Ad-RTS-hIL-12 + veledimex, including the 20 mg expansion cohort in patients with recurrent or progressive glioblastoma. Median overall survival of all patients receiving intratumoral Ad-RTS-hIL-12 with 20 mg of orally administered veledimex was maintained at 12.5 months, with a mean follow-up time of 9.2 months. Register for free on DailyStockTracker.com and download the latest research report on ZIOP at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All